Dr. Rosenzweig, MD graduated from Harvard College, where he majored in biochemistry and molecular biology. He received his medical degree from Harvard Medical School and completed his residency in internal medicine and fellowship in cardiovascular medicine at the Massachusetts General Hospital (MGH). Additional research training included a one-year predoctoral fellowship in neurosciences at the University of Pennsylvania and postdoctoral training in the laboratories of Drs. Jonathan and Christine Seidman, as well as Dr. Michael Gimbrone, all at Harvard Medical School.

Dr. Rosenzweig is the inaugural Director of the Stanley and Judith Frankel Institute for Heart and Brain Health (Frankel IHBH) at the University of Michigan Medical Center. Previous leadership roles include having served as Chief of Cardiology, Co-Director of the Corrigan Minehan Heart Center and Director of Cardiovascular Research at MGH as well as the Paul Dudley White Professor of Medicine at Harvard Medical School (2015-2022). He also has served as the inaugural Director of the Program in Cardiovascular Gene Therapy at MGH, a Trustee of the Harvard Clinical Research Institute (an academic clinical research organization), an Executive Committee member of the Harvard Stem Cell Institute and its Cardiovascular Program Leader, as well as the Director of Cardiovascular Research and Associate Chief of Cardiology at the Beth Israel Deaconess Medical Center in Boston. Dr. Rosenzweig is also a member of the Leducq Foundation Scientific Advisory Committee and the American Heart Association Basic Sciences Council leadership.

Dr. Rosenzweig’s research has focused on identifying novel mechanisms and therapeutic targets in heart failure, using the exercised heart to understand what keeps hearts healthy. Of particular interest is how dysregulation of common pathways, such as those involved in metabolism, cellular senescence, or inflammation, can drive disease in multiple organs, including the brain and heart, since targeting such pathways could have broad clinical benefits. Dr. Rosenzweig is deeply committed to realizing the translational potential of basic science discoveries. His work has led to multiple patent awards, licensed approaches to mutation detection, and new therapeutic strategies being investigated in clinical trials. He has led successful partnerships with industry, served on industry advisory panels, and co-founded a recently funded biotech start-up focused on small molecule therapies for Long QT Syndrome. Dr. Rosenzweig has been a principal investigator for multiple successful research consortia including an international Leducq Foundation Network of Research Excellence, multiple NIH U-awards, an AHA Strategically Focused Research Network Center, and multiple NIH T32 training grants. His research has been continuously funded by the NIH for over 30 years.